论文部分内容阅读
目的探讨瑞舒伐他汀强化治疗对冠心病并发阵发性心房颤动的临床疗效。方法回顾性分析68例冠心病并发阵发性房颤患者的临床资料,随机分治疗组和对照组各34例,治疗组给予瑞舒伐他汀20mg/d,对照组给予瑞舒伐他汀10mg/d。随访1年,检测两组患者治疗前、后第1、6、12个月C反应蛋白(CRP)水平;测定治疗前及治疗12个月后血脂、左心房内径、左心室射血分数;观察阵发性房颤的再发率、转化为持续性房颤的发生率。结果与对照组相比,治疗组CRP明显下降,观察期内阵发性房颤再发率、转化为持续性房颤的发生率明显下降。结论冠心病并发阵发性房颤的患者采用瑞舒伐他汀强化治疗能显著降低炎症因子CRP,减少阵发性房颤的复发、进展。
Objective To investigate the clinical effect of rosuvastatin on patients with coronary heart disease complicated with paroxysmal atrial fibrillation. Methods A retrospective analysis of 68 cases of coronary heart disease complicated with paroxysmal atrial fibrillation in patients with clinical data were randomly divided into treatment group and control group, 34 cases, the treatment group given rosuvastatin 20mg / d, the control group given rosuvastatin 10mg / d. The levels of C-reactive protein (CRP) were measured at 1, 6 and 12 months after treatment in both groups. Blood lipids, left atrium diameter and left ventricular ejection fraction were measured before and 12 months after treatment. The recurrence rate of paroxysmal atrial fibrillation, into the incidence of persistent atrial fibrillation. Results Compared with the control group, the treatment group CRP decreased significantly during the observation period, the recurrence rate of paroxysmal atrial fibrillation, conversion to persistent atrial fibrillation incidence decreased significantly. Conclusions Treatment with rosuvastatin in patients with coronary heart disease complicated with paroxysmal atrial fibrillation can significantly reduce the inflammatory factor CRP and reduce the recurrence and progression of paroxysmal atrial fibrillation.